Dear Colleagues,

In arrhythmogenic cardiomyopathy, characterized by fibrofatty replacement of the myocardium, diagnostic efforts are difficult and many different steps are required to provide an accurate diagnosis.

In attempting to make the diagnosis of arrhythmogenic cardiomyopathy, standard ECG, echocardiography, right ventricular angiography, and electrophysiological studies can provide strong diagnostic evidence.

The most relevant diagnostic method is cardiac MRI with late enhancement. Each of these diagnostic methods should be reported in advance.

Therapeutic options include ICD implantation, ablation of ventricular tachycardia using an endocardial or epicardial approach, pharmacological approaches (amiodarone, flecainide, and beta-blockers), and most importantly the management of heart failure. In nearly 40% of cases, different forms of arrhythmogenic cardiomyopathy (arrhythmogenic biventricular cardiomyopathy and arrhythmogenic left ventricular cardiomyopathy) result in severe heart failure that can only be managed with early prophylactic treatment determined by genetic findings (phospholamban, lamin A/C, and filamin C mutations).

I am pleased to invite you to submit original manuscripts on the subject of “Arrhythmogenic Cardiomyopathy: Diagnosis and Therapy—Volume 2” for this Special Issue. Full length papers, communications, and comprehensive reviews are welcome.

Dr. Stefan Peters and Prof. Domenico Corrado
Guest Editors